Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
64 USD | -0.39% |
|
+5.44% | +1.93% |
16/07 | JPMorgan Adjusts Price Target on Incyte to $59 From $60, Maintains Neutral Rating | MT |
16/07 | Goldman Sachs Adjusts Price Target on Incyte to $61 From $60, Maintains Neutral Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.93% | 14.39B | |
+7.75% | 100B | |
+8.42% | 42.34B | |
-13.04% | 32.76B | |
+80.80% | 29.46B | |
-10.92% | 16.31B | |
-6.77% | 12.23B | |
+177.16% | 10.47B | |
+4.12% | 8.97B | |
-56.13% | 8.84B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Transcript : Incyte Corporation Presents at 39th Annual JPMorgan Virtual Healthcare Conference, Jan-11-2021 04